48,341 Shares in Anika Therapeutics Inc. $ANIK Acquired by Hsbc Holdings PLC

Hsbc Holdings PLC acquired a new position in shares of Anika Therapeutics Inc. (NASDAQ:ANIK) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 48,341 shares of the biotechnology company’s stock, valued at approximately $464,000. Hsbc Holdings PLC owned approximately 0.36% of Anika Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently added to or reduced their stakes in ANIK. Quarry LP purchased a new stake in shares of Anika Therapeutics in the third quarter valued at $71,000. CWM LLC grew its holdings in shares of Anika Therapeutics by 14.5% during the fourth quarter. CWM LLC now owns 8,537 shares of the biotechnology company’s stock valued at $82,000 after buying an additional 1,080 shares in the last quarter. Occudo Quantitative Strategies LP acquired a new position in Anika Therapeutics during the third quarter valued at $95,000. Ieq Capital LLC acquired a new position in Anika Therapeutics during the fourth quarter valued at $97,000. Finally, Tudor Investment Corp ET AL purchased a new stake in Anika Therapeutics in the 3rd quarter worth about $107,000. 91.53% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Anika Therapeutics

In other news, Director John B. Henneman III bought 5,000 shares of the company’s stock in a transaction on Friday, May 1st. The shares were bought at an average cost of $14.66 per share, with a total value of $73,300.00. Following the transaction, the director directly owned 54,871 shares in the company, valued at approximately $804,408.86. This trade represents a 10.03% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Stephen D. Griffin purchased 12,200 shares of the business’s stock in a transaction dated Thursday, April 30th. The shares were purchased at an average cost of $12.29 per share, with a total value of $149,938.00. Following the completion of the purchase, the chief executive officer directly owned 36,163 shares in the company, valued at approximately $444,443.27. This represents a 50.91% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 12.08% of the company’s stock.

Analyst Ratings Changes

Several research firms have weighed in on ANIK. Wall Street Zen cut Anika Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Anika Therapeutics in a report on Wednesday, June 24th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $17.00.

Anika Therapeutics Stock Down 0.7%

Anika Therapeutics stock opened at $15.82 on Friday. The company’s fifty day simple moving average is $14.96 and its 200-day simple moving average is $13.30. Anika Therapeutics Inc. has a 12 month low of $7.87 and a 12 month high of $16.49. The stock has a market cap of $210.56 million, a P/E ratio of -20.03 and a beta of 0.23.

Anika Therapeutics (NASDAQ:ANIK) last posted its quarterly earnings results on Wednesday, April 29th. The biotechnology company reported $0.27 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.34. Anika Therapeutics had a negative net margin of 9.52% and a negative return on equity of 5.90%. The business had revenue of $29.61 million for the quarter, compared to the consensus estimate of $28.14 million. On average, equities research analysts expect that Anika Therapeutics Inc. will post -0.74 earnings per share for the current fiscal year.

About Anika Therapeutics

Anika Therapeutics, Inc is a life sciences company specializing in the development and commercialization of hyaluronic acid–based therapeutic products. The company focuses on orthobiologics and medical devices designed to support joint health, tissue repair and surgical applications. Anika’s proprietary hyaluronan technology serves as the foundation for products aimed at alleviating pain associated with osteoarthritis and enhancing healing in musculoskeletal and ophthalmic surgeries.

The company’s core product portfolio includes injectable viscosupplements such as Monovisc® and Orthovisc®, which are indicated for the relief of knee osteoarthritis pain, as well as Euflexxa®, approved for osteoarthritis of the knee in various international markets.